fmc-376
frontier medicines
['fmc-376']
frontier medicines presents new preclinical data on its development candidate, fmc-376, a dual krasg12c inhibitor, at the 2023 aacr annual meeting - is a highly selective, direct dual inhibitor designed to rapidly and completely block both the active an... 
CEO Of Digital Media Online